GÜLİS KAVADAR, Nil ÇAĞLAR, Şule TÜTÜN, Şeyma ÖZEN, Demet DEMİRCİOĞLU

Efficacy of conventional ultrasound therapy on myofascial pain syndrome: a placebo controlled study

Amaç: Miyofasiyal ağrı sendromu (MFAS), çizgili kas içinde tetik noktalar ile karakterize bir kompleks ağrı sendromudur. Ça- lışmamızda, fizik tedavide kullanılan temel cihazlardan biri olan ultrasonun (US) tetik nokta tedavisindeki etkinliği araştırıldı. Gereç ve Yöntem: Trapez kası üst liflerinde saptanan tetik noktalara bağlı MFAS tanısı konulan 59 hasta (49 kadın, 10 erkek) randomize olarak tedavi (n=30) ve kontrol grubu (n=29) olarak iki gruba ayrıldı. Tedavi grubuna 15 gün boyunca, günde bir kez 6 dakika süreyle 1.5 Watt/cm2 dozunda, 1 MHz devamlı konvansiyonel US tedavisi, kontrol grubuna ise aynı sürede plasebo US tedavisi uygulandı. Tedavi öncesi, tedavi sonrası ve tedaviden üç ay sonra vizüel analog skala ile olguların istirahat ve aktivite sırasındaki ağrı düzeyi, sıfır-beş skalası ile tetik nokta hassasiyeti, algometre ile tetik nokta üzerindeki basınç ağrı eşiği ve Beck depresyon ölçeği ile depresyon düzeyleri, tedavi grubunu bilmeyen bir klinisyen tarafından değerlendirildi. Bulgular: Olguların yaş ortalaması tedavi grubunda 37.43±9.07, kontrol grubunda 35.83±5.68 idi. Tedavi öncesi değerlerle karşılaştırıldığında, tedaviden sonra ve üç ay sonraki kontrollerde her iki grupta da ağrı yakınmaları, tetik nokta hassasiyeti ve depresyon düzeyinde anlamlı bir azalma (p

Efficacy of conventional ultrasound therapy on myofascial pain syndrome: a placebo controlled study

Objectives: Myofascial pain syndrome (MPS) is a complex pain syndrome characterized with trigger points (TP) in skeletal muscles. We aimed to assess the efficacy of ultrasound (US) therapy, which is one of the main devices used in physical medi- cine and rehabilitation, for the treatment of TP in MPS. Methods: Fifty nine patients (49 females, 10 males) with active TP on the upper trapezius fibers were randomized into the treatment (n=30) and the control groups (n=29). The treatment group received conventional US therapy for 6 minutes, on 1.5 Watt/cm2 dose with 1 MHz frequency for 15 days whereas a placebo US therapy was administered to the control group. Prior to the treatment, immediately and 3 months later pain severity during rest and physical activity was assessed with visual analog scale (VAS), TP tenderness was measured with 05 scale, pressure pain threshold (PPT) was analyzed with algometer and the depression level was evaluated with Becks depression questionnaire (BDP) by a clinician blinded to the groups. Results: The mean age of the patients were 37.43±9.07 and 35.83±5.68 years, in the treatment and control groups, respectively. Compared to the pre-treatment values VAS, 05 scale and BDP scores decreased (p<0.01) along with an increase in PPT (p<0.01) in both groups at the follow-up visits. 05 scales and BDP scores were significantly lower and PPT was significantly higher in the treatment group, compared to the control group (p<0.001).

PDF

___

1. Stecco A, Gesi M, Stecco C, Stern R. Fascial components of the myofascial pain syndrome. Curr Pain Headache Rep 2013;17(8):352. 2. Jaeger B. Myofascial trigger point pain. Alpha Omegan. 2013;106(1-2):1422. 3. Tough EA, White AR, Richards S, Campbell J. Variability of criteria used to diagnose myofascial trigger point pain syndrome--evidence from a review of the literature. Clin J Pain 2007;23(3):27886. 4. Borg-Stein J, Simons DG. Focused review: myofascial pain. Arch Phys Med Rehabil 2002;83(3 Suppl 1):409. 5. Pace MC, Mazzariello L, Passavanti MB, Sansone P, Bar- barisi M, Aurilio C. Neurobiology of pain. J Cell Physiol 2006;209(1):812. 6. Fernández-de-las-Peñas C, Dommerholt J. Myofascial trig- ger points: peripheral or central phenomenon? Curr Rheu- matol Rep 2014;16(1):395. 7. Simons DG, Travell JG, Simons LS. Travell and Simons Myo- fascial Pain and Dysfunction; the Trigger Point Manual. Vol. 1, 2 ed. Williams & Wilkins, Baltimore 1999. 8. Unalan H, Majlesi J, Aydin FY, Palamar D. Comparison of high-power pain threshold ultrasound therapy with lo- cal injection in the treatment of active myofascial trigger points of the upper trapezius muscle. Arch Phys Med Re- habil 2011;92(4):65762. 9. Gonçalves MC, Teixeira da Silva EG, Chaves TC, Dach F, Spe- ciali JG. Static ultrasound and manual therapy in refractory migraine. Case report. Rev Dor. Sao Paulo 2012;13(1):804. 10. Dixon JS, Bird HA. Reproducibility along a 10 cm vertical visual analogue scale. Ann Rheum Dis 1981;40(1):879. 11. Treaster D, Marras WS, Burr D, Sheedy JE, Hart D. Myofas- cial trigger point development from visual and postural stressors during computer work. J Electromyogr Kinesiol 2006;16(2):11524. 12. Fischer AA. Documentation of myofascial trigger points. Arch Phys Med Rehabil 1988;69(4):28691. 13. Tegin B. Turkish version of Beck Depression Inventory. Un- published Doctorate Thesis 1980. 14. Pillay GM.The treatment of myofascial pain syndrome us- ing therapeutic ultrasound, on upper trapezius trigger points :a double-blinded placebo controlled study com- paring the pulsed and continous waveforms of ultrasound. Dept. Chiropractic, Durban Institute of Technology 2003. 15. Ilter L, Dilek B, Batmaz I, Ulu MA, Sariyildiz MA, Nas K, et al. Efficacy of Pulsed and Continuous Therapeutic Ultrasound in Myofascial Pain Syndrome: A Randomized Controlled Study. Am J Phys Med Rehabil 2015;94(7):54754. 16. Draper DO, Mahaffey C, Kaiser D, Eggett D, Jarmin J. Ther- mal ultrasound decreases tissue stiffness of trigger points in upper trapezius muscles. Physiother Theory Pract 2010;26(3):16772. 17. Srbely JZ, Dickey JP. Randomized controlled study of the antinociceptive effect of ultrasound on trigger point sensi- tivity: novel applications in myofascial therapy? Clin Reha- bil 2007;21(5):4117. 18. Robertson VJ, Baker KG. A review of therapeutic ultrasound: effectiveness studies. Phys Ther 2001;81(7):133950. 19. van der Windt DA, van der Heijden GJ, van den Berg SG, ter Riet G, de Winter AF, Bouter LM. Ultrasound therapy for musculoskeletal disorders: a systematic review. Pain 1999;81(3):25771. 20. Hammer W, MS, DC. Therapeutic Ultrasound Effective for Musculoskeletal Problems. Dynamic Chiropractic 2011;26:29. 21. Gam AN, Johannsen F. Ultrasound therapy in musculoskel- etal disorders: a meta-analysis. Pain 1995;63(1):8591. 22. Kısaoglu S, Erdem HR, Goncu G, Yorgancıoglu RZ. The ef- fectiveness of ultrasound treatment in myofascial pain syndrome. Romatizma 2000;(2)15:1237. 23. Clement Jones V, Rees LH. Neuroendocrine correlates of the endorphins and enkephalins. Int Clinical Neuroendo- crinology 1982;2:139209. 24. Fields HL, Levine JD. Placebo analgesia-a role for endor- phins? Trends Neuro Sci 1984;7:2713. 25. Kokkotou E, Conboy LA, Ziogas DC, Quilty MT, Kelley JM, Davis RB, et al. Serum correlates of the placebo effect in irritable bowel syndrome. Neurogastroenterol Motil 2010;22(3):28581. 26. Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK. Neurobiological mechanisms of the placebo effect. J Neu- rosci 2005;25(45):10390402. 27. Simons DG, Mense S. Diagnosis and therapy of myofascial trigger points. [Article in German] Schmerz 2003;17(6):419 24. [Abstract] 28. Woolf CJ. Central sensitization: implications for the diag- nosis and treatment of pain. Pain 2011;152(3 Suppl):215. 29. Hsieh YL. Reduction in induced pain by ultrasound may be caused by altered expression of spinal neuronal nitric ox- ide synthase-producing neurons. Arch Phys Med Rehabil 2005;86(7):13117. 30. Kumar SP, Saha S. Mechanism-based Classification of Pain for Physical Therapy Management in Palliative care: A Clini- cal Commentary. Indian J Palliat Care 2011;17(1):806.